Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended			99 Months Ended
	Mar. 08, 2023	Jan. 31, 2015	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Prior period performance obligation revenue recognized			$ 4,800		$ 3,200
Overpayment reimbursement liability			2,200			$ 2,200	$ 1,800
Revenue recognized			(2)
Total revenues			237,577		329,219
Pfizer | Product
Disaggregation of Revenue [Line Items]
Revenue recognized						$ 85,000
Initial upfront payment		$ 295,000
Maximum milestone payments		$ 275,000		$ 85,000
Merck | Other License Agreement
Disaggregation of Revenue [Line Items]
Total revenues	$ 50,000		50,000
Rayaldee
Disaggregation of Revenue [Line Items]
Revenue recognized			6,600		5,100
Total revenues			14,281		13,479
Transfer of intellectual property and other
Disaggregation of Revenue [Line Items]
Total revenues			64,826		5,962
Transfer of intellectual property and other | Vifor | Product
Disaggregation of Revenue [Line Items]
Total revenues			7,000		3,000
Maximum milestone payments			7,000
Transfer of intellectual property and other | Nicoya | Product
Disaggregation of Revenue [Line Items]
Maximum milestone payments			2,500
Transfer of intellectual property and other | Pfizer | Product
Disaggregation of Revenue [Line Items]
Total revenues			$ 1,800		$ 2,200